Packing-Line Improvement Based on a Fault-Tree Analysis Approach - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Packing-Line Improvement Based on a Fault-Tree Analysis Approach
This article focuses on upgrading and improving a packing process to comply with current good manufacturing practices. The authors sought to maintain proper quality assurance for finished products.


Pharmaceutical Technology
Volume 3, Issue 32

Authors' note

A colleague of the authors suggested a test of the end-of-line weighing station during packing-process validation by moving several MUBs along the line with one leaflet missing from each. The authors stand by the original concept followed in this study. Key process components must be qualified before the packing line is validated as a whole. The process is validated by integrating all qualified components and simulating normal process function as closely as possible without compromising the regular course of the process by adding an extra challenge. The authors believe that the technical balance's sensitivity for detecting missing components should be determined in advance. Then, one can focus on the objective of process validation, which is to evaluate the packing operator's ability to deliver completed MUBs throughout the simulation runs. Nevertheless, the above suggestion could be analyzed in a further revalidation of justified in-process changes.

Arturo Toledo Rivero* is the head of the research and development department, Nelson Sierra Prado is the head of the validation group, and Yohann Pérez Molina is a quality engineering specialist at LIORAD Laboratories, Ave. 27A No. 26402, La Lisa, Havana, Cuba, tel. 1537 2717935, fax 1537 2717899,
Ian Toledo de Zayas is a logistics specialist at DUJO Business Group.

*To whom all correspondence should be addressed.

Submitted: Aug. 8, 2007. Accepted: Nov. 1, 2007.

References

1. European Commission, "Production", in Volume 4—Medicinal Products for Human and Veterinary Use: Good Manufacturing Practice, (European Commission, Brussels, Belgium, 2005), pp. 47–49.

2. ISPE, "ISPE Baseline Guide—Packaging, Labeling, and Warehousing," (ISPE, Tampa, FL, vol. 7, rev. B, 2005).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here